Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its vector-adjuvant-antigen standardized technology proprietary oral vaccine platform. The company's product pipeline in...
Q1 2026
May 7, 2026
FY 2025
Mar 13, 2026
Q4 2025
Q3 2025
Nov 13, 2025
Q2 2025
Aug 13, 2025